Benzinga | Jun 28, 2021 05:42AM EDT

Stifel Upgrades Nektar Therapeutics to Buy, Raises Price Target to $24

Stifel analyst Benjamin Burnett upgrades Nektar Therapeutics (NASDAQ:NKTR) from Hold to Buy and raises the price target from $22 to $24.